Article and Video CATEGORIES
On July 19th, we'll run our next webinar program, featuring GRACE Vice President Dr. Vivek Mehta, who is a radiation oncologist and Director of the Center for Advanced Targeted Radiotherapy at Swedish Cancer Institute in Seattle, WA. He'll be covering several timely topics, ranging from stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer, integration of new radiation technologies for locally advanced lung cancer, potentially curative focal radiation for "oligometastatic" lung cancer, and the challenging option of reirradiation within a previously radiated field. He'll speak on the evidence we have and the promise these approaches hold, as well as the status of this work, from still being the subject of clinical trials to being integrated into off protocol cancer management.
Dr. Mehta will cover these topics over about 40-45 minutes, followed by a question and answer session with our live audience. Registration is free (through this link), and for anyone unable to make the live presentation or who would just like to review the program later, these presentations and the question and answer sessions will be made into podcasts that will be freely available.
This educational activity is made possible by the partnership of the LUNGevity Foundation with GRACE, the Global Resource of Advancing Cancer Education.
We hope to have you join us!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…